NASDAQ Companies

Lexeo Therapeutics gains intellectual property rights including current and future clinical data from ongoing Weill Cornell Medicine investigator-initiated trial of […]

– Ziftomenib is the first investigational treatment to be granted Breakthrough Therapy Designation for NPM1-mutant AML – – Registration-directed trial […]

First Quarter Net Revenue Range Improved to $20.0 Million to $21.0 Million First Quarter Adjusted EBITDA Loss Range Improved to […]

ALMATY, Kazakhstan, April 22, 2024 (GLOBE NEWSWIRE) — The Board of Directors of JSC Kaspi.kz (Nasdaq: KSPI) hereby announces the […]

First Quarter Highlights Net income of $15.3 million, or $0.48 per diluted share; return on average assets (“ROAA”) of 1.23%; return […]

RESEARCH TRIANGLE PARK, N.C., April 22, 2024 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will […]

ALMATY, Kazakhstan, April 22, 2024 (GLOBE NEWSWIRE) — Joint Stock Company Kaspi.kz (“Kaspi.kz”, “we”, or the “Company”) (Nasdaq: KSPI) which […]

Company plans to initiate SERENITY At-Home pivotal Phase 3 safety trial with 120 mcg dose following recent meeting with FDA […]

Plus now has $23 million in active awards support for the Company’s targeted radiotherapeutic pipeline Funding for pediatric brain cancer […]

PHILADELPHIA, April 22, 2024 (GLOBE NEWSWIRE) — Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on improving […]